查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401993

2030年糖尿病肾臟病的全球市场预测：按类型、诊断类型、治疗、给药途径、配销通路、最终用户和地区进行分析

Diabetic Nephropathy Market Forecasts to 2030 - Global Analysis By Type, By Diagnosis Type, By Treatment, Route of Administration, Distribution Channel, End Users and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球糖尿病肾臟病市场规模为 27 亿美元，预计到 2030 年将达到 41 亿美元，预测期内复合年增长率为 5.8%。

糖尿病肾臟病是由糖尿病引起的肾臟疾病，其特征是长期高血糖导致肾臟损伤。透过定期筛检进行早期发现可以及时进行干预，包括改变生活方式和药物治疗，以预防或减缓进展并降低与晚期肾臟疾病相关的併发症的风险。

根据国际糖尿病联盟 (IDF) 的数据，40% 的糖尿病患者在阶段可能会出现肾衰竭。此外，大约80%的末期肾功能衰竭是由糖尿病和高血压引起的。

提高意识和主动筛检计划

宣传宣传活动正在教育人们有关糖尿病相关肾臟併发症的风险，并增加接受定期筛检以早期发现的人数。早期发现可以及时干预和管理，有可能减缓糖尿病肾臟病变的进展并减少併发症。主动筛检不仅有助于改善患者的治疗结果，还可以提高医疗保健系统在糖尿病肾臟病变管理方面的整体有效性。这项背景凸显了预防性医疗保健措施的重要性，使个人能够主动应对糖尿病肾臟病并促进更好的长期健康结果。

治疗费用高

糖尿病肾臟病变的治疗很复杂，需要药物治疗、改变生活方式，在严重的情况下还需要肾臟替代治疗，导致高昂的医疗费用。与持续就诊、药物以及透析或肾臟移植的可能性相关的经济负担可能会限制获得最佳治疗，特别是对于那些无法负担费用的人来说。这些财务障碍可能导致治疗延迟或不充分，进而对患者的治疗结果产生负面影响。

政府糖尿病管理倡议

随着全球各国政府优先考虑公共卫生，旨在预防和管理糖尿病的倡议将直接使市场受益。支持宣传宣传活动、糖尿病教育和无障碍筛检计画的政策有助于糖尿病肾臟病患者的早期发现和介入。政府支持的医疗保健计划和药品津贴改善了患者获得治疗的机会，并创造了有利于市场成长的环境。医疗保健当局和製药业在这些倡议上的合作不仅将解决糖尿病的社会负担，还将创建一个框架来支持糖尿病肾臟病变管理解决方案的扩展。

与某些药物相关的副作用

儘管药物治疗在糖尿病肾臟病变的治疗中发挥重要作用，但药物的潜在副作用可能导致患者焦虑、违规和停止治疗。胃肠道紊乱、低血糖和肾臟併发症等副作用可能会损害患者的整体健康。这项威胁凸显了开发和处方具有良好安全性的药物的重要性。製药公司和医疗保健提供者必须优先考虑研究和创新，以最大限度地减少副作用，并确保治疗的好处大于潜在的风险。

COVID-19 的影响：

COVID-19 的爆发对糖尿病肾臟病市场产生了多方面的影响。医疗保健服务的中断、患者不愿寻求非紧急护理以及将资源转移到流行病管理上，这些都共同影响了糖尿病肾臟病的诊断和管理。然而，这场大流行也强调了主动管理的重要性，并强调了远端医疗和数位健康解决方案的机会，以加强糖尿病肾臟病变的远端监测和患者照护。

尿液检查领域预计将在预测期内成为最大的领域

尿液检查领域预计将出现良好的成长。这些测试，例如蛋白尿和蛋白尿评估，可以帮助及早发现糖尿病引起的肾臟损伤。监测尿液中蛋白质水平是否异常有助于医疗专业人员评估肾臟病的进展。定期尿液检查可以及时干预和个体化治疗计划，有助于更好地管理糖尿病肾臟病变并改善患者预后。它作为一种非侵入性、经济高效的诊断工具，支持有效的医疗保健策略来对抗糖尿病併发症。

预计医院业在预测期内复合年增长率最高。

预计医院产业在预测期内将以最快的复合年增长率成长。这些医疗机构提供基本服务，例如诊断筛检、肾臟病专家咨询以及获得各种治疗性介入。该医院也为重症病例提供透析和肾臟移植等更先进的治疗。此外，该医院也是病患教育中心，有助于提高人们对糖尿病肾臟病的认识和主动管理。医院、医疗保健专业人员和患者之间的合作对于应对糖尿病肾臟病变带来的挑战和改善患者的治疗效果至关重要。

占有率最大的地区

预计北美市场在预测期内将继续占据大部分市场占有率。该地区先进的医学研究能力有助于早期检测、创新治疗方法和强劲的医药市场。政府措施、医疗保健政策和人们对糖尿病的认识不断提高，进一步推动了市场成长。随着高龄化和对预防保健的重视，北美在製定有效管理糖尿病肾臟病变的进展和解决方案方面继续发挥关键作用。

复合年增长率最高的地区：

预计亚太地区在预测期内复合年增长率最高。该地区糖尿病盛行率不断上升，特别是在中国和印度等国家，增加了对糖尿病肾臟病变管理的需求。政府倡议、改善的医疗基础设施以及增加的研发投资都有助于市场的扩张。随着该地区应对糖尿病流行，亚太地区糖尿病肾臟病市场出现了显着增长，为医疗保健提供者和製药公司提供了满足人们不断变化的医疗保健需求的机会。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球糖尿病肾臟病市场：依类型

  • 1型糖尿病
  • 2型糖尿病
  • 其他类型

第六章全球糖尿病肾臟病市场：依诊断类型

  • 验血
  • 尿液检查
  • 影像检查
  • 肾功能检查
  • 切片检查
  • 其他诊断类型

第七章全球糖尿病肾臟病市场：依治疗分类

  • 药品
    • 利尿剂
    • 抗氧化发炎调节剂
    • 血管收缩素受体阻断剂
    • 血管张力素转化酵素抑制剂（ACE抑制剂）
    • 肾素抑制剂
    • 钙离子通道阻断剂
    • 其他药品
  • 肾臟透析
  • 移植

第八章全球糖尿病肾臟病变市场：依给药途径

  • 口服
  • 家长
  • 其他给药途径

第九章全球糖尿病肾臟病变市场：依配销通路

  • 线上药房
  • 零售药房

第 10 章全球糖尿病肾臟病市场：依最终用户分类

  • 医院
  • 居家护理
  • 专业中心
  • 其他最终用户

第十一章全球糖尿病肾臟病变市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • GlaxoSmithKline Plc.
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Hikma Pharmaceuticals PLC
  • Mylan NV
  • Novartis AG
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Bristol Myers Squibb Company
Product Code: SMRC24513

According to Stratistics MRC, the Global Diabetic Nephropathy Market is accounted for $2.7 billion in 2023 and is expected to reach $4.1 billion by 2030 growing at a CAGR of 5.8% during the forecast period. Diabetic Nephropathy is a kidney condition resulting from diabetes, characterized by kidney damage due to prolonged high blood sugar levels. Its early detection through regular screening allows for timely intervention, including lifestyle modifications and medications, preventing or slowing progression and reducing the risk of complications associated with advanced kidney disease.

According to the International Diabetes Federation (IDF), 40% of diabetics may experience kidney failure in its ultimate stages. Furthermore, about 80% of end-stage renal failure is caused by diabetes and hypertension, either together or individually.

Market Dynamics:

Driver:

Increased awareness and proactive screening programs

Awareness campaigns educate individuals about the risks of kidney complications associated with diabetes, more people are encouraged to undergo regular screenings for early detection. Early identification enables prompt intervention and management, potentially slowing the progression of diabetic nephropathy and reducing associated complications. Proactive screening not only contributes to better patient outcomes but also enhances the overall effectiveness of healthcare systems in managing diabetic nephropathy. This driver underscores the importance of preventive healthcare measures, empowering individuals to take proactive steps in addressing diabetic nephropathy and promoting better long-term health outcomes.

Restraint:

High treatment costs

The complex nature of managing diabetic nephropathy, which may involve medications, lifestyle modifications, and, in severe cases, renal replacement therapies, contributes to elevated healthcare expenses. The financial burden associated with consistent medical appointments, medications, and potential dialysis or kidney transplantation can limit access to optimal care, especially for individuals with limited financial resources. This economic barrier may result in delayed or inadequate treatment, adversely impacting patient outcomes.

Opportunity:

Government initiatives for diabetes management

As governments globally prioritize public health, initiatives aimed at preventing and managing diabetes directly benefit the market. Policies supporting awareness campaigns, diabetes education, and accessible screening programs contribute to early detection and intervention in diabetic nephropathy cases. Government-backed healthcare programs and subsidies for medications can enhance patient access to treatment, fostering a more conducive environment for market growth. Collaboration between healthcare authorities and the pharmaceutical industry to align with these initiatives not only addresses the societal burden of diabetes but also creates a supportive framework for the expansion of diabetic nephropathy management solutions.

Threat:

Side effects associated with certain medications

Pharmaceutical interventions play a crucial role in managing diabetic nephropathy, the potential adverse effects of medications may lead to patient apprehension, non-compliance, or discontinuation of treatment. Side effects such as gastrointestinal issues, hypoglycemia, and renal complications can compromise the overall well-being of patients. This threat underscores the importance of developing and prescribing medications with favorable safety profiles. Pharmaceutical companies and healthcare providers must prioritize research and innovation to minimize side effects, ensuring that the benefits of treatment outweigh potential risks.

COVID-19 Impact:

The COVID-19 pandemic has had a multifaceted impact on the Diabetic Nephropathy Market. Disruptions in healthcare services, patient hesitancy to seek non-urgent medical care, and diversion of resources to pandemic management have collectively affected the diagnosis and management of diabetic nephropathy. However, the pandemic has also emphasized the importance of proactive management and highlighted opportunities for telemedicine and digital health solutions to enhance remote monitoring and patient care in the diabetic nephropathy landscape.

The urine test segment is expected to be the largest during the forecast period

The urine test segment is expected to have a lucrative growth. These tests, such as albuminuria and proteinuria assessments, help in early detection of kidney damage caused by diabetes. Monitoring the presence of abnormal levels of proteins in the urine aids healthcare professionals in assessing the progression of nephropathy. Regular urine testing allows for timely intervention and personalized treatment plans, contributing to better management of diabetic nephropathy and improved patient outcomes. It serves as a non-invasive and cost-effective diagnostic tool, supporting effective healthcare strategies in combating this complication of diabetes.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. These healthcare institutions provide essential services, including diagnostic screenings, consultations with nephrologists, and access to a range of therapeutic interventions. Hospitals also facilitate more advanced treatments like dialysis and kidney transplantation for severe cases. Additionally, they serve as hubs for patient education, contributing to increased awareness and proactive management of diabetic nephropathy. The collaborative efforts of hospitals, healthcare professionals, and patients are critical in addressing the challenges posed by diabetic nephropathy and improving patient outcomes.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share. The region's advanced medical research capabilities contribute to early detection, innovative therapies, and a robust pharmaceutical market. Government initiatives, healthcare policies, and a heightened awareness of diabetes further support the market's growth. With a growing aging population and a focus on preventive healthcare, North America continues to be a key player in shaping advancements and solutions for the effective management of diabetic nephropathy.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The region's rising prevalence of diabetes, particularly in countries like China and India, amplifies the demand for diabetic nephropathy management. Government initiatives, improving healthcare infrastructure, and growing investments in research and development contribute to the market's expansion. As the region grapples with the diabetes epidemic, the Diabetic Nephropathy Market in Asia Pacific is positioned for substantial growth, presenting opportunities for healthcare providers and pharmaceutical companies to address the evolving healthcare needs of the population.

Key players in the market:

Some of the key players in Diabetic Nephropathy market include F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GlaxoSmithKline Plc., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Mylan N.V., Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Bayer AG and Bristol Myers Squibb Company.

Key Developments:

In March 2023, Novartis announced that it had submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for renoprotective effects of sevelamer carbonate, a phosphate binder, for the treatment of diabetic nephropathy.

In January 2023, Boehringer Ingelheim and Eli Lilly and Company announced that US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. These tablets have been investigated as a possible therapy to reduce the chance of cardiovascular death and kidney disease progression in adults with chronic kidney disease.

In December 2022, Bayer launched Finerenone under the brand name Kerendia in India. Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Types Covered:

  • Type-1 Diabetes
  • Type-2 Diabetes
  • Other Types

Diagnosis Types Covered:

  • Blood Test
  • Urine Test
  • Imaging Test
  • Renal Function Testing
  • Kidney Biopsy
  • Other Diagnosis Types

Treatments Covered:

  • Medication
  • Kidney Dialysis
  • Transplant

Route of Administrations Covered:

  • Oral
  • Parental
  • Other Route of Administrations

Distribution Channels Covered:

  • Online Pharmacy
  • Retail Pharmacy

End Users Covered:

  • Hospitals
  • Homecare
  • Speciality Centres
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Diabetic Nephropathy Market, By Type

  • 5.1 Introduction
  • 5.2 Type-1 Diabetes
  • 5.3 Type-2 Diabetes
  • 5.4 Other Types

6 Global Diabetic Nephropathy Market, By Diagnosis Type

  • 6.1 Introduction
  • 6.2 Blood Test
  • 6.3 Urine Test
  • 6.4 Imaging Test
  • 6.5 Renal Function Testing
  • 6.6 Kidney Biopsy
  • 6.7 Other Diagnosis Types

7 Global Diabetic Nephropathy Market, By Treatment

  • 7.1 Introduction
  • 7.2 Medication
    • 7.2.1 Diuretics
    • 7.2.2 Antioxidant Inflammation Modulator
    • 7.2.3 Angiotensin Receptor Blockers
    • 7.2.4 Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
    • 7.2.5 Renin Inhibitors
    • 7.2.6 Calcium Channel Blockers
    • 7.2.7 Other Medications
  • 7.3 Kidney Dialysis
  • 7.4 Transplant

8 Global Diabetic Nephropathy Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parental
  • 8.4 Other Route of Administrations

9 Global Diabetic Nephropathy Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Pharmacy
  • 9.3 Retail Pharmacy

10 Global Diabetic Nephropathy Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Homecare
  • 10.4 Specialty Centers
  • 10.5 Other End Users

11 Global Diabetic Nephropathy Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 F. Hoffmann-La Roche Ltd
  • 13.2 Fresenius Kabi AG
  • 13.3 GlaxoSmithKline Plc.
  • 13.4 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • 13.5 Hikma Pharmaceuticals PLC
  • 13.6 Mylan N.V.
  • 13.7 Novartis AG
  • 13.8 Pfizer Inc
  • 13.9 Teva Pharmaceutical Industries Ltd.
  • 13.10 Bayer AG
  • 13.11 Bristol Myers Squibb Company

List of Tables

  • Table 1 Global Diabetic Nephropathy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Diabetic Nephropathy Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Diabetic Nephropathy Market Outlook, By Type-1 Diabetes (2021-2030) ($MN)
  • Table 4 Global Diabetic Nephropathy Market Outlook, By Type-2 Diabetes (2021-2030) ($MN)
  • Table 5 Global Diabetic Nephropathy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 6 Global Diabetic Nephropathy Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 7 Global Diabetic Nephropathy Market Outlook, By Blood Test (2021-2030) ($MN)
  • Table 8 Global Diabetic Nephropathy Market Outlook, By Urine Test (2021-2030) ($MN)
  • Table 9 Global Diabetic Nephropathy Market Outlook, By Imaging Test (2021-2030) ($MN)
  • Table 10 Global Diabetic Nephropathy Market Outlook, By Renal Function Testing (2021-2030) ($MN)
  • Table 11 Global Diabetic Nephropathy Market Outlook, By Kidney Biopsy (2021-2030) ($MN)
  • Table 12 Global Diabetic Nephropathy Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 13 Global Diabetic Nephropathy Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 14 Global Diabetic Nephropathy Market Outlook, By Medication (2021-2030) ($MN)
  • Table 15 Global Diabetic Nephropathy Market Outlook, By Diuretics (2021-2030) ($MN)
  • Table 16 Global Diabetic Nephropathy Market Outlook, By Antioxidant Inflammation Modulator (2021-2030) ($MN)
  • Table 17 Global Diabetic Nephropathy Market Outlook, By Angiotensin Receptor Blockers (2021-2030) ($MN)
  • Table 18 Global Diabetic Nephropathy Market Outlook, By Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors) (2021-2030) ($MN)
  • Table 19 Global Diabetic Nephropathy Market Outlook, By Renin Inhibitors (2021-2030) ($MN)
  • Table 20 Global Diabetic Nephropathy Market Outlook, By Calcium Channel Blockers (2021-2030) ($MN)
  • Table 21 Global Diabetic Nephropathy Market Outlook, By Other Medications (2021-2030) ($MN)
  • Table 22 Global Diabetic Nephropathy Market Outlook, By Kidney Dialysis (2021-2030) ($MN)
  • Table 23 Global Diabetic Nephropathy Market Outlook, By Transplant (2021-2030) ($MN)
  • Table 24 Global Diabetic Nephropathy Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 25 Global Diabetic Nephropathy Market Outlook, By Oral (2021-2030) ($MN)
  • Table 26 Global Diabetic Nephropathy Market Outlook, By Parental (2021-2030) ($MN)
  • Table 27 Global Diabetic Nephropathy Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 28 Global Diabetic Nephropathy Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 29 Global Diabetic Nephropathy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 30 Global Diabetic Nephropathy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 31 Global Diabetic Nephropathy Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 Global Diabetic Nephropathy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 33 Global Diabetic Nephropathy Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 34 Global Diabetic Nephropathy Market Outlook, By Specialty Centers (2021-2030) ($MN)
  • Table 35 Global Diabetic Nephropathy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.